Collegium Pharmaceutical, Inc. COLL
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Collegium Pharmaceutical, Inc. (COLL) is a healthcare company listed in the US with a market value of about $787M. In the twelve months to September 30, 2026 it had revenue of $815M and net income of $38M, a net margin of 4.7%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is value (5/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 23.2, a price to free cash flow of 2.3, 5-year revenue growth of 20% a year, a 5-year average ROIC of 33%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 182% above the current price.
About Collegium Pharmaceutical
Collegium Pharmaceutical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $2M in 2016 to $781M in 2025, growth of about 97.5% a year. It was profitable in 5 of the last 10 years in our data. Its share count rose by 17% over three years (dilution for shareholders).
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Checks not passed
- Profit margin improving
- Profitable 5 years in a row
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $815M | $781M | $631M | $567M | $464M | $277M | $310M | $297M | $280M | $28M | $2M |
| Net income | $38M | $63M | $69M | $48M | -$25M | $72M | $27M | -$23M | -$39M | -$75M | -$94M |
| Free cash flow | $336M | $328M | $203M | $274M | $123M | $102M | $88M | $21M | $164M | -$68M | -$76M |
| EPS (diluted) | $1.09 | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 | $0.76 | $-0.68 | $-1.19 | $-2.47 | $-3.88 |
| Net margin | 4.7% | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% | -7.7% | -14.0% | -262.9% | -5504.1% |
| ROIC | — | 39.7% | 50.6% | 52.4% | 14.2% | 6.6% | 27.9% | -21.8% | -15.8% | -57.3% | -53.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $44.00, 74% above the current price; targets range from $28.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $7.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Collegium Pharmaceutical’s P/E ratio?
About 23.2, based on the last twelve months of diluted earnings per share (forward P/E about 3.6).
Is Collegium Pharmaceutical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 182% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Collegium Pharmaceutical pay a dividend?
Not currently.
Is Collegium Pharmaceutical a good stock to buy?
We do not give buy or sell advice. Collegium Pharmaceutical scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.